Extracellular matrix gene expression profiling using microfluidics for colorectal carcinoma stratification by Hayes, Christopher J. et al.
Extracellular matrix gene expression profiling using
microfluidics for colorectal carcinoma stratification
Christopher J. Hayes,1,2 Catriona M. Dowling,1,2,3 Susan Dwane,1
Mary E. McCumiskey,1,4 Shona M. Tormey,4 B. Anne Merrigan,4
John C. Coffey,2,3,4,5 Patrick A. Kiely,1,2,3,5 and Tara M. Dalton1,a)
1Stokes Laboratories, Bernal Institute, University of Limerick, Limerick, Ireland
2Graduate Entry Medical School, University of Limerick, Limerick, Ireland
3Health Research Institute, University of Limerick, Limerick, Ireland
4Department of Surgery, University Hospital Limerick, Limerick, Ireland
54i Centre for Interventions in Infection, Inflammation and Immunity, Graduate Entry
Medical School, University of Limerick, Limerick, Ireland
(Received 16 August 2016; accepted 14 October 2016; published online 31 October 2016)
In cancer, biomarkers have many potential applications including generation of a
differential diagnosis, prediction of response to treatment, and monitoring disease
progression. Many molecular biomarkers have been put forward for different
diseases but most of them do not possess the required specificity and sensitivity. A
biomarker with a high sensitivity has a low specificity and vice versa. The
inaccuracy of the biomarkers currently in use has led to a compelling need to
identify more accurate markers with diagnostic and prognostic significance. The
aim of the present study was to use a novel, droplet-based, microfluidic platform to
evaluate the prognostic value of a panel of thirty-four genes that regulate the compo-
sition of extracellular matrices in colorectal carcinoma. Our method is a novel
approach as it uses using continuous-flowing Polymerase Chain Reaction for the
sensitive detection and accurate quantitation of gene expression. We identified a
panel of relevant extracellular matrix genes whose expression levels were measured
by real-time quantitative polymerase chain reaction using Taqman
VR
reagents in
twenty-four pairs of matched colorectal cancer tumour and associated normal tissue.
Differential expression patterns occurred between the normal and malignant tissue
and correlated with histopathological parameters and overall surgical staging. The
findings demonstrate that a droplet-based microfluidic quantitative PCR system ena-
bles biomarker classification. It was further possible to sub-classify colorectal can-
cer based on extracellular matrix protein expressing groups which in turn correlated
with prognosis. VC 2016 Author(s). All article content, except where otherwise
noted, is licensed under a Creative Commons Attribution (CC BY) license (http://
creativecommons.org/licenses/by/4.0/). [http://dx.doi.org/10.1063/1.4966245]
INTRODUCTION
Colorectal cancer is a significant cause of mortality worldwide with more than 746 000
cases in men and 614 000 cases in women diagnosed annually.1 The biomarkers used in colo-
rectal cancer mainly aim to either (a) aid in determining suitability for chemotherapy or (b)
accurately determine prognosis. Biomarkers are sub classified into clinical (emergency versus
elective presentation), serologic (tumour antigens such as carcinoembryonic antigen), or histo-
logic (including nodal status, lymph node ratio, lymphovascular invasion, and perineural
invasion). Nevertheless, these biomarkers have limited utility as they are not accurate at the
individual level. To overcome this, genetic-based biomarkers have been characterised. These
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include microRNAs, single nucleotide polymorphisms, and RNA-based determination of gene
expression. The convergence of these efforts with the development of array-based technologies
has led to the development of omics, or high-throughput based, biomarkers. However, these are
hampered by lack of consensus between laboratories and are not in routine clinical use given
costs and other factors. Currently, the consensus is that biomarkers have failed to yield a valid
basis for personalised medicine and so the approach to their development must be refreshed.
Since its introduction in 1992,2 qPCR-based technologies have been widely exploited in
the evaluation of biomarkers,3–5 where potential markers are measured with greater accuracy to
yield gene sets or signatures that can distinguish between a predefined defined subsets of
tumours.6 Micro total analysis systems, such as those utilising droplet microfluidics, provide
clinical benefits in the setting of colorectal cancer by performing higher throughputs with
enhanced data analysis capabilities. Furthermore, the quantity of available tissue has become a
critical factor in –omnic studies as we are now detecting cancer in polyps. Polyps can easily be
removed but we cannot accurately determine the probability that the tumour will have spread to
nodes within the associated mesentery. This spread is thought to be a critical step in metastasis
development. As the risk of spread is unknown, subjecting patients to resection of the segment
of colon or mesentery can expose patients to increased and unnecessary risks of complications
or death. Therefore, by scaling of the reaction from the microliter down to the nanolitre range
dramatically reduces the required volume of reagents and samples,7 reducing the overall cost
per reaction and conserving the clinical samples. Histologically, cancer can be diagnosed in a
few hundred cells, so developing an approach to determine nodal status accurately with mini-
mal tissue allows that these technologies can be preferred to obtain improved biological and
translatable results.
To date, we have extensively characterised the role of several biomarkers in colorectal
malignancy. Our research group has recently identified significant prognostic biomarkers in
colorectal cancer8,9 and established consensus profiles and associations with prognostic and pre-
dictive properties in colon and rectal adenocarcinomas.10,11 Therefore, the hypothesis of this
study is to use microfluidic droplets acting as distinct miniature reactors to identify differen-
tially expressed extracellular-matrix (ECM) genes in colorectal cancer tissue and matched
patient normal tissue to determine if differential expression could be correlated with an
increased metastatic potential. The extracellular-matrix (ECM) has important roles in regulating
normal cell and tissue development and function.12,13 ECM components constantly interact with
epithelia as ligands for receptors including integrins. In this manner, they instigate intracellular
activities related to a vast array of biologic functions, including tissue development and homeo-
stasis.14 In fact, the ECM influences almost all cellular behaviour and is critical during major
developmental processes.15,16 However, in solid organ malignancy, ECM–based molecular and
cellular interactions can be dramatically altered in a manner that potentiates metastasis develop-
ment.17 The metastatic process requires ECM remodelling, basement membrane degradation,
and enhanced tumour cell motility.18 Cell shape, function, proliferation, migration, and apopto-
sis are all influenced by cell-ECM interactions. These relationships are altered in solid organ
malignancies. Therefore, the identification of prominent ECM tumour markers that derive
biological insight into tumour development and progression would be of clinical value.
MATERIALS AND METHODS
Patients and Tissue Samples: Colorectal cancer tissue and paired adjacent physiologically
normal mucosa tissue samples were collected (ethical approval number 73/11) from a heteroge-
neous group of 24 patients at different stages of malignancy, undergoing colorectal resection at
University Hospital Limerick. Primarily, the tumours are adenocarcinomas. After removal of
the colon and associated mesentery, the specimen was opened. Mucosal samples were taken
from the tumour and normal mucosa at a distance of 10 cm from the tumour. Samples were
immediately placed in Allprotect
VR
Tissue Reagent (Qiagen, Hilden, Germany) and stored in a
80 C freezer.
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RNA extraction and cDNA Synthesis: Frozen tissue was immersed in liquid nitrogen and
ground into powder. Lysis buffer was added to tissue and the sample transferred to tubes. Total
ribonucleic acid (RNA) was extracted using RNeasy Plus Mini Kit
VR
(Qiagen, Hilden, Germany)
according to manufacturer’s instructions. RNA was evaluated for purity on the NanoDropTM
1000 Spectrophotometer 3.7 (Thermo Fisher, Massachusetts, United States). RNA has its
absorption maximum at 260Nm and the ratio of the absorbance at 260Nm and 280Nm is used
to assess the RNA purity of an RNA preparation. RNA quality was evaluated through visualiza-
tion of the 28S:18S ribosomal RNA ratio on a 1% agarose gel. cDNA synthesis was performed
using Superscript
VR
VILO cDNA Synthesis Kit (Thermo Fisher, Carlsbad, USA) according to
the manufacturer’s protocol. Reactions were incubated for 25 C for 10min followed by 60 C
for 45min and 72 C for final denaturation for 15min. Samples were stored at 20 C.
Endogenous reference controls: Relative quantification is based on the expression levels of a
target gene versus one or more reference gene(s), and in many experiments it is adequate for inves-
tigating physiological changes in gene expression levels.19 Peptidylprolyl Isomerase A (PPIA) and
Hypoxanthine guanine phosphoribosyl transferase 1 (HPRT1) have been showed previously to be
stably expressed in a large cohort of colorectal tissues,20,21 and so were chosen to normalise
expression values in the present study. The use of multiple reference genes increases the accuracy
of quantitation compared to the use of a single reference gene, especially when the aim is to show
relatively small fold-changes in RNA levels.22 Further to this, our research group have character-
ised the expression level of nine candidate reference genes and determined their stability in malig-
nant and normal colorectal tissue.23 From this, Phosphoglycerate Kinase 1 (PGK1), Glucuronidase
Beta (GUSB), and PPIA were ranked as the most stable genes between normal and cancerous
tissue. Therefore, PGK1 and GUSB were used as additional reference genes. A list of selected
reference genes can be seen in Table I.
qPCR of mRNA: The instrument that has been developed on which the PCR will be per-
formed24 is a droplet based microfluidic platform that performs qPCR in a continuous flowing
process. The reaction droplets (300gl) are surrounded by an immiscible oil to prevent contam-
ination and carryover. Micro-scale polytetrafluoroethylene (PTFE) capillary tubing is integrated
into dipping heads that are attached to modular robotic stages. The stages programmed
sequence allows dipping into the solutions and aspirates predefined quantities of patient cDNA
and nuclease free water (35gl:100gl), gene expression assay primer-probe mix (15gl) (TaqManVR
Gene Expression Assays, Thermo Fisher, Massachusetts, United States), and Mastermix (150gl)
(TaqMan
VR
Gene Expression Master Mix
VR
-Thermo Fisher, Massachusetts, United States). The
individual droplets are then combined at the liquid bridge which consists of capillaries where
the droplets are suspended before merging in a free-balanced system.25 The single PCR reac-
tions are then conveyed through the system to the thermal zone. Thermal cycling is performed
in a flowing serpentine cycler, which gives superior thermal performance because of the relative
size of the droplet resulting in more sensitive experiments. The temperature blocks of 95 C
(denaturisation) and 65 C (annealing) are isothermal to prevent a non-uniform temperature field
which may lead to low amplification efficiency of nucleic acids and even non-specific PCR
products due to insufficient annealing temperature of the PCR process.26 Each cycle through a
serpentine performs one cycle of PCR and there are 40 cycles in total. To detect the droplet
signal a bio-fluorescence detection platform, comprising of reflectance probes, fibre optical
cores, and high resolution cameras, analyse each microfluidic reactor droplet. From this data,
TABLE I. Reference genes used for normalisation.
Gene name Gene symbol Location Assay ID bp References
Phosphoglycerate kinase 1 PGK1 Xq13.3 Hs00943178_g1 73 111, 21, and 23
Peptidylprolyl isomerase A PPIA 7p13 Hs04194521_s1 97
Glucuronidase beta GUSB 7q21.11 Hs00939627_m1 96
Hypoxanthine guanine phosphoribosyl transferase 1 HPRT1 Xq26.1 Hs02800695_m1 82
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the amplification s-curves for each sample are generated. A baseline is then set and the s-curve
is post processed to output a threshold cycle (Ct) value or, according to the MIQE guidelines,27
a quantification cycle (Cq) value, which is indicative of the number of RNA targets in the ini-
tial samples. The Cq is determined from a log-linear plot of PCR signal versus the cycle num-
ber. The background levels are normally determined from the first triplicate no-template-control
(NTC) droplets in a run. This is subtracted from the subsequent ROX reference dye normalisa-
tion value. The DDCq method is currently the most commonly used method for studies that
report changes in the expression of genes of interest relative to a reference gene.28 For studies
performed on the platform, the relative expression levels of the target genes are calculated
using the Livak and Schmittgen method29 using the formula 2–(DDCt) where
DDCq ¼ ½ðCq target genenormal sampleÞ  ðCq reference genenormal sampleÞ
 ½ðCq target genecancer sampleÞ  ðCq reference genecancer sampleÞ:
Statistical Analysis: Statistical analysis was carried out using IBM SPSS Statistics 21
(SPSS, Inc.,) The mean of triplicates was used for statistical analysis where the mean difference
between the matched samples, the standard deviation, standard error, and 95% confidence inter-
val of this mean difference is evaluated, respectively. The distribution of the data is tested for
normality using histograms for both normal and tumour samples and also using the Shapiro-
Wilk test (used where n< 50) for normality to determine whether the distribution of the differ-
ences in the dependent variable between the two related groups was approximately normally
distributed. Whisker plots were generated and interpreted to indicate if there were any
“outliers” in the data sets. Outliers were removed on the criteria of being two times the stan-
dard deviation of the dataset. Parametric tests (Paired-sample student t-tests) and non-
parametric tests (Wilcoxon signed-rank) were used to assess related samples based on the distri-
bution of the data. If homogeneity of variances was violated, then separate parametric and non-
parametric tests were performed to assess effect variations. A two-tailed p-value <0.05 was
considered statistically significant. Correlations between parameters and ECM gene expression
levels in the samples analysed were determined by Pearson product-moment correlation coeffi-
cient, r. P values <0.05 were considered statistically significant.
RESULTS
Gene Selection criteria: A detailed analysis of extracellular matrisome literature reviews
and published colorectal cancer gene expression profiling studies was undertaken to identify
key ECM genes involved in colorectal cancer formation and development. Genes that code for
constituents such as integrins, collagens, proteases, and growth factors were selected to be
included in the panel. Furthermore, an analysis of current ECM gene expression arrays such as
the Taqman
VR
and Qiagen
VR
ECM and Adhesion Molecule arrays (Catalogue number: 4414133
and PAHS-013ZA)30,31 was reviewed to support hypotheses developed for which genes could
be most influential in the metastatic spread of the disease. A list of the selected genes for analy-
sis in this study can be seen in Table II with references for studies which show specific genetic
dysregulation.
DIFFERENTIAL GENE EXPRESSION IN MATCHED SAMPLES
RNA expression levels of the panel of thirty-four ECM genes were measured by qPCR in
the twenty-four malignant tissue samples and their corresponding normal tissue. The proportion
of tissue represented by epithelium or stroma (i.e., the epithelial-stromal ratio) can affect the
expression of genes. Expression levels of Cytokeratin-18 (KRT18) and Vimentin (VIM) were
assessed by qPCR to approximate the epithelial and stromal tissue components of each sam-
ple9,32 with average composition for the twenty four samples shown to be consistent and can be
seen in Figure 1. Differential gene expression greater than two-fold difference between normal
and malignant tissue was observed in twenty-two genes. The differences identified in expression
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were statistically significant in the case of fourteen genes (Figure 2). These genes have varying
biological functions and code for cell surface proteins, growth factors, and proteins involved in
tissue remodelling and cell adhesion. The greatest difference in gene expression was observed
in MMP7 (þ31 fold, p¼<0.001) between the matched tumour and normal mucosa in this
study. IL-8 expression was significantly up-regulated (þ18-fold, p¼<0.001) and ITGBL1
expression was shown to be increased (þ11-fold, p¼ 0.003) in malignant versus matched nor-
mal tissue. MMP9 expression was observed to be upregulated (þ7-fold, p¼ 0.02) in the malig-
nant tissue as was COL1A1 expression (þ6-fold, p¼ 0.039) and ITGA2 (4-fold, p¼ 0.007).
CXCR2 (4-fold, p¼ 0.022), SPARC (3.5-fold, p¼ 0.033), and RACK1 (2.5 fold, p¼ 0.019)
were also identified as being upregulated in the matched comparison. Conversely, decreased
expression levels were observed in six of the genes in the ECM panel. IGF-1 expression levels
were lower (8-fold, p¼ 0.007) in cancer tissue than in the normal tissue. Decreases in
TABLE II. Candidate cancer-related genes that may play roles in regulating the composition of the ECM and be involved
in the progression and development of cancer.
Gene name Gene symbol Location Assay ID bp References
Cadherin-2 CDH2 18q11.2 Hs00983056_m1 66 65 and 66
Carcinoembryonic antigen-related
cell adhesion molecule 1
CEACAM1 19q13.2 Hs00989786_m1 75 58 and 67
CD9 Molecule CD9 12p13.3 Hs00233521_m1 72 68 and 69
Chemokine (C-X-C motif) receptor 2 CXCR2 2q35 Hs01891184_s1 64 70 and 71
Collagen, type I, alpha 1 COL1A1 17q21.33 Hs00164004_m1 66 30 and 72
Collagen, type III, alpha 1 COL3A1 2q31 Hs00943809_m1 65 50 and 73
Epidermal growth factor EGF 4q25 Hs01099999_m1 70 74 and 75
Epidermal growth factor receptor EGFR 7p12 Hs01076090_m1 57 76 and 77
Insulin-like growth factor 1 IGF1 12q23.2 Hs01547656_m1 68 78 and 79
Insulin-like growth factor 1 receptor IGF1R 15q26.3 Hs00609566_m1 64 55, 80, and 81
Insulin-like growth factor 2 IGF2 11p15.5 Hs04188276_m1 83 82 and 83
Insulin-like growth factor 2 receptor IGF2R 6q26 Hs00974474_m1 59 84 and 85
Insulin-like growth factor binding protein 2 IGFBP2 2q35 Hs01040719_m1 54 86 and 87
Insulin-like growth factor binding protein 3 IGFBP3 7p12.3 Hs00365742_g1 79 87 and 88
Insulin-like growth factor binding protein 4 IGFBP4 17q21.2 Hs01057900_m1 81 87
Integrin, alpha 2 ITGA2 5q11.2 Hs00158127_m1 67 77 and 89
Integrin, alpha 5 ITGA5 12q11-q13 Hs01547673_m1 54 50 and 90
Integrin, alpha 8 ITGA8 10p13 Hs00233321_m1 89 30
Integrin, alpha V ITGAV 2q31-q32 Hs00233808_m1 64 77 and 90
Integrin, beta 1 ITGB1 10p11.2 Hs00559595_m1 75 30 and 91
Integrin, beta 4 ITGB4 17q25 Hs00173995_m1 58 30 and 92
Integrin, beta 5 ITGB5 3q21.2 Hs00174435_m1 78 30 and 50
Integrin, beta-like 1 ITGBL1 13q33 Hs01557019_m1 71 31
Interleukin-8 IL8 4q13-q21 Hs00174103_m1 101 93 and 94
Laminin, alpha 1 LAMA1 18p11.3 Hs00300550_m1 77 30 and 95
Matrix metalloproteinase 2 MMP2 16q12.2 Hs01548727_m1 65 96–98
Matrix metalloproteinase 3 MMP3 11q22.3 Hs00968305_m1 126 93 and 99
Matrix metalloproteinase 7 MMP7 11q22.2 Hs01042796_m1 64 39 and 100
Matrix metalloproteinase 9 MMP9 20q13.12 Hs00234579_m1 54 101 and 102
Periostin, osteoblast specific factor POSTN 13q13.3 Hs01566750_m1 67 103 and 104
Protein tyrosine kinase 2 PTK2 8q24.3 Hs01056457_m1 76 105 and 106
Receptor of activated protein kinase C RACK1 5q35.3 Hs00272002_m1 66 107 and 108
Secreted protein, acidic, cysteine-rich SPARC 5q31.3-q32 Hs00234160_m1 76 90 and 109
Vascular endothelial growth factor A VEGFA 6p12 Hs00900055_m1 59 109 and 110
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expression levels for EGF (5 fold, p¼ 0.014) and EGFR (3-fold, p¼ 0.05) were also
observed. CEACAM1 was also identified as being decreased (4-fold, p¼ 0.048). ITGA8 gene
expression levels were shown to be downregulated (3.6-fold, p¼ 0.003) in the cohort. This
information is tabulated in Table V.
ANALYSIS OF EXPRESSION COORDINATION AND GENE NETWORKING
After the initial gene expression levels were determined by experimental means, gene pairs
which had similar expression patterns from the fourteen gene panel were sought. The expres-
sion levels in the 24 patient cohort were assessed using a Pearson’s correlation coefficient test
for significance (p-value< 0.05). The strongest positive relationships were observed between
COL1A1 and SPARC expression (q¼ 0.763, p-value¼<0.001) and COL1A1 and RACK1
(q¼ 0.451, p-value¼ 0.032). MMP7 and ITGA2 also showed a correlation (q¼ 0.552, p-value
¼ 0.018). Correlations between ITGBL1 and both SPARC expression (q¼0.720, p-value
¼ 0.001) and EGF (q¼0.699, p-value¼<0.001) also emerged as being statistically signifi-
cant. A strong positive correlation was observed between EGF and its receptor EGFR expres-
sion (q¼0.470, p-value¼ 0.032). The associations between the significant gene expression
arrays are shown in Table III.
Subsequently, the patient cohort was stratified according to UICC staging to identify further
differential expression patterns (Figure 3). The cohort was categorised based on the histopatho-
logical diagnoses as follows; a) Group 1; benign disease samples including diverticulosis,
hyperplasia, tubulovillous adenoma (TVA) polyps and Stage I samples (n¼ 6) b) Group 2;
stage II carcinomas (n¼ 11) c) Group 3; stage III and stage IV advanced carcinomas (n¼ 7).
Gene expression was compared between malignant and matched normal tissue. The number of
genes differentially expressed increased sequentially from Group 1 to Group 3. Group 1; ECM
gene dysregulation between the normal and cancer samples for patients was noted only in an
upregulation of IL-8 (15-fold, p¼ (0.05). Group 2; Statistically significant up-regulation was
observed for MMP7 (48 fold, p¼ 0.004), IL-8 (17-fold, p¼ 0.015), COL1-A1 (8.7 fold,
p¼ 0.049), LAMA1 (11-fold, p¼ 0.033), ITGBL1 (8-fold, p¼ 0.016), MMP9 (5.2 fold,
p¼ 0.05), ITGA2 (5.1 fold, p¼ 0.039), and COL3A1 (4-fold, p¼ 0.041). Genes that were
observed to be statistically downregulated for Group 2 samples included EGF (7.4 fold,
p¼ 0.004), IGF1 (4.7 fold, p¼ 0.034), and CEACAM1 (4.5-fold, p¼ 0.044). Group 3;
Upregulation of IL-8 (25 fold, p¼ 0.002), ITGBL1 (22.5-fold, p¼ 0.021), MMP7 (17.8-fold,
p¼ 0.035), SPARC (5.6 fold, p¼ 0.05), ITGA2 (5.1 fold, p¼ 0.029), RACK1 (5 fold,
p¼ 0.006), and ITGAV (2 fold, p¼ 0.012). Downregulation of IGF1 (11.7 fold, p¼ 0.04),
LAMA1 (9.4 fold, p¼ 0.08), ITGA8 (7.8 fold, p¼ 0.048), and EGF (7 fold, p¼ 0.03).
Patient demographics, including histopathological diagnoses, are summarised in Table IV.
FIG. 1. Figure shows the determination of epithelial and stromal content of the samples. Legend shows the average percent-
age of each in the normal and cancer samples. Minimal difference in levels of each is observed.
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ASSOCIATION BETWEEN MALIGNANT SAMPLE GENE EXPRESSION
AND HISTOPATHOLOGICAL PARAMETERS
Tumour diameter: The gene expression of three ECM genes in the panel,
IGF1(r¼0.596, p¼ 0.009), ITGBL1 (r¼ 0.669, p¼ 0.005), and VEGF (r¼0.487, p¼ 0.04),
correlated with the diameter of the samples which were recorded during surgical examination.
The tumour size at the largest point was recorded in millimetres (mm) with three categories of
<30mm, 30–40mm, and >40mm. IGF1 decreased expression (13 fold) and ITGBL1
increased expression (26.4-fold) were observed to be present in tumours with a diameter greater
than 40mm.
Mucinous Component: From the cohort, four of the twenty tumours were documented as
having a mucinous component and all were Stage III carcinomas. Colorectal mucinous carcino-
mas present at a more advanced stage, predominantly in men, with higher right colon location
FIG. 2. Gene expression fold change levels for the patients included in the study showing statistically significant differ-
ences between normal mucosa and matched tumour samples from our patient cohort. We took the average fold change rela-
tive to normal tissue sample and normalised to the geometric mean of the reference genes.
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TABLE III. Genes with dysregulated expression from Figure 1 are shown. Statistically significant correlated (co-expressed) genes are highlighted in bold.
Correlations
ITGA2 ITGA8 ITGBL1 IGF1 SPARC EGF EFGR MMP7 MMP9 COL1A1 CEACAM1 RACK1 IL8 CXCR2
ITGA2 Pearson Correlation 1
Sig. (2-tailed)
ITGA8 Pearson Correlation 0.082 1
Sig. (2-tailed) 0.711
ITGBL1 Pearson Correlation 0.157 0.339 1
Sig. (2-tailed) 0.495 0.123
IGF1 Pearson Correlation 0.012 0.371 0.285 1
Sig. (2-tailed) 0.955 0.074 0.199
SPARC Pearson Correlation 0.211 0.264 .493a 0.235 1
Sig. (2-tailed) 0.333 0.213 0.02 0.269
EGF Pearson Correlation 0.086 0.077 .487a 0.072 0.047 1
Sig. (2-tailed) 0.718 0.739 0.029 0.756 0.84
EFGR Pearson Correlation 0.227 0.161 0.172 0.32 0.277 .470a 1
Sig. (2-tailed) 0.298 0.453 0.445 0.127 0.191 0.032
MMP7 Pearson Correlation .522a 0.081 0.003 0.102 0.197 0.051 0.049 1
Sig. (2-tailed) 0.018 0.726 0.988 0.659 0.391 0.836 0.834
MMP9 Pearson Correlation 0.146 0.053 0.053 0.041 0.298 0.017 0.169 0.051 1
Sig. (2-tailed) 0.527 0.814 0.82 0.857 0.178 0.946 0.453 0.831
COL1A1 Pearson Correlation 0.079 0.323 0.174 0.292 .763b 0.13 0.283 0.131 0.277 1
Sig. (2-tailed) 0.728 0.133 0.438 0.176 0.01 0.585 0.191 0.571 0.212
CEACAM1 Pearson Correlation 0.161 0.225 0.097 0.215 0.203 0.194 0.037 0.224 0.295 0.143 1
Sig. (2-tailed) 0.462 0.291 0.667 0.312 0.341 0.401 0.865 0.329 0.183 0.515
RACK1 Pearson Correlation 0.274 0.125 0.09 0.108 0.357 0.002 0.077 0.066 0.354 .451a 0.258 1
Sig. (2-tailed) 0.206 0.561 0.692 0.614 0.087 0.993 0.721 0.777 0.106 0.031 0.223
IL8 Pearson Correlation 0.141 0.313 0.21 0.311 0.099 0.35 0.073 0.352 0.058 0.073 0.145 0.094 1
Sig. (2-tailed) 0.521 0.136 0.349 0.139 0.644 0.12 0.734 0.117 0.798 0.742 0.5 0.663
CXCR2 Pearson Correlation 0.392 0.1 0.403 0.124 0.141 0.054 0.369 0.105 0.017 0.289 0.11 0.25 0.118 1
Sig. (2-tailed) 0.064 0.642 0.063 0.564 0.512 0.815 0.076 0.649 0.941 0.181 0.61 0.238 0.583
aStatistically significant (p < 0.05), Correlation is significant at the 0.05 level (2-tailed).
bCorrelation is significant at the 0.01 level (2-tailed).
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FIG. 3. The figure shows expression fold-difference for the gene panel between normal and cancer samples when samples
are categorised according to UICC staging. Normal samples are normalised to one and highlighted in red, Group 1 is
highlighted in green, Group 2 is highlighted purple, and Group 3 is highlighted in blue. Statistical significance is also
shown (p-value; *¼<0.05; **¼<0.01).
TABLE IV. Clinicopathological data of patients used for gene expression analysis qPCR in our study.
Number of patients (n¼ 24)
TVA/other pathology 6(25%)
Carcinoma 18(75%)
Age(years)
Range 45–83
Mean þ SD 65.87(9.85)
Median 65.5
Mode 56
Gender(n5 24)
Male 15
Female 9
UICC staging(n5 24)
N/A 5 (21%)
Stage I 1(4%)
Stage II 11(46%)
Stage III 6(25%)
Stage IV 1(4%)
Location(n5 24)
Right colon (male/female) 9 (6/3)
Left colon (male/female) 5(4/1)
Rectum/Sigmoid(male/female) 9(4/5)
Total Colectomy 1(1/0)
Tumour diameter(n5 24)
N/A 6
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rate, and a worse overall 5-year survival rate than the non-mucinous colorectal cancer.33 Three
of the four patients with mucinous component were male. ITGBL1 and ITGA8 expressions corre-
lated with whether or not a mucinous component was present. Increased expression in ITGBL1
(r¼ 0.669, p¼ 0.005) was observed in mucin positive tumours and average expression of ITGA8
was decreased (r¼ 0.655, p¼ 0.002). Three of the four patients received chemotherapy.
Differentiation: The expression levels of three genes showed a moderate correlation with
the level of differentiation which was recorded during surgical resection. Upregulation of
COL3A1 was significantly associated with poorer differentiation (r¼ 0.469, p¼ 0.024) along
with upregulation of MMP9 (r¼ 0.423, p¼ 0.05). It has been shown34 that increased levels of
MMP-9 correlate with poorer differentiation. A slight increase in IGF-1R (r¼ 0.533, p¼ 0.049)
levels also correlated with poorer differentiation.
Recurrence: Three of the samples in the cohort were taken from patients who later pre-
sented with a recurrence of the carcinoma. PTK2 (r¼ 0.435, p¼ 0.043) levels in these patients
were shown to be elevated in comparison with patients whose cancers had not recurred.
Age: Patients were categorised into two groups of being up to and including sixty-four
years of age and sixty-five and older. Increased MMP7 expression correlated with increased age
TABLE IV. (Continued.)
Number of patients (n¼ 24)
<30mm 6
30–40mm 3
>40mm 7
Unknown 2
Tumour grade(n5 24)
N/A 5
T1 1
T2 4
T3 11
T4 2
Unknown 1
Nodal status(n5 24)
NX 4
N0 12
N1 6
N2 2
Differentiation(n5 24)
Well-moderate 9
Moderate 10
Moderate-poor 5
Invasive(n5 24)
Yes 16
No 8
Mucin secretion(n5 24)
Mucinous 5
Not stated 19
Lymphovascular invasion(n5 24)
N/A 6
Present 3
Absent 9
Suspicious 2
Not stated 4
054124-10 Hayes et al. Biomicrofluidics 10, 054124 (2016)
in the cohort (r¼ 0.488, p¼ 0.018). Patients aged sixty-four and under had an average increase
of 10-fold expression of MMP7 while patients aged sixty-five and over had an average of 40-
fold increase. CDH2 levels were also correlated (r¼ 0.490, p¼ 0.015) with age where patients
under 64 had six fold decreased CDH2 expression than people aged over 65. Increased IGFBP3
expression (þ2 fold) correlated (r¼ 0.473, p¼ 0.023) with an increased age compared to the
younger group.
Gender: IGFBP3 expression levels were noted to correlate (r¼ 0.424, p¼ 0.044) with
patient gender with male patients having an increased expression (þ4-fold) compared to
females
Lymph Node Status: In nonmetastatic colorectal cancer, lymph node status is the strongest
pathologic predictor of patient outcome and is used for determining the most appropriate adju-
vant treatment for patients. In the cohort, patient’s lymph nodes were examined for abnormal
cellular behaviour and inflammation. The nodal status was determined using the American Joint
Committee on Cancer (AJCC) TNM system where the "N" portion of this classification system
refers to the nodal status indicating the presence, if any, of cancer spread to other lymph nodes.
The system is: NX: Regional lymph nodes cannot be assessed, N0: Cancer has not spread to
regional lymph nodes, N1: Cancer has spread to 1 to 3 lymph nodes, and N2: Cancer has
spread to 4 to 9 lymph nodes. Four patients were classified as NX, twelve patients were classi-
fied as N0, six were classified as N1, and 2 were classified as N2. The expression of PTK2, or
Focal Adhesion Kinase (FAK) as it is more commonly known, showed a step-wise increase
from N0 to N1 to N2 (r¼ 0.587, p¼ 0.006). A stepwise decrease was also observed for ITGA8
for N0 to N2 (r¼0.523, p¼ 0.018).
Invasiveness: The invasiveness of the tumour is closely linked to the size and the grade of
the tumour and is determined by whether or not the tumour penetrates the basement membrane
and/or muscle layers in the lumen of the colon. For this study, a tumour was categorised as
being invasive or not. In the twenty-four patient cohort, nineteen samples are documented to be
invasive malignancies of varying degree. The depth of invasion was not recorded. These sam-
ples were analysed to determine if changes in expression for the ECM genes correlated with
the invasiveness of a cancer. SPARC and COL1A1 expression levels were shown to be
increased significantly in samples which were invasive (r¼ 0.465, p¼ 0.022) (r¼ 0.494,
p¼ 0.017).
Perineural Invasion (PNI): PNI is grossly underreported in CRC and could serve as an
independent prognostic factor of outcomes in these patients.35 The PNI absence was reported in
six of the 20 tumour samples. Perineural invasion was not stated for fourteen others. MMP-9
levels were significantly decreased in patients with no perineural invasion (r¼ 0.481,
p¼ 0.037). Increases in MMP-9 aid a cancer cell’s progression to metastasis and have been
shown36 to correlate with increases in perineural invasion in the literature.
Stage: The clinical staging of the patients disease was also determined by the AJCC TNM
system. Stage grouping can be seen in Table IV. ITGBL1 expression (r¼ 0.588, p¼ 0.013) was
identified as showing a stepwise increase in expression which correlated with the staging of the
patient cohort with an 8 fold increase in expression for patients with Stage II and 22 fold
increase for Stage III in comparison to Stage I. LAMA1 expression showed an increase in Stage
II (þ20-fold) but a significant decrease in expression in Stage III (40 fold) (r¼ 0.509,
p¼ 0.037).
Grade: ITGA2, ITGB1, and CD9 gene expression levels were correlated with the grade of the
malignant samples analysed albeit with a small sample size. ITGA2 was observed be lower in T3
and T4 tumour samples in comparison to T1 and T2 tumour samples (r¼0.657, p¼ 0.004),
while the levels of ITGB1 replicated this pattern (r¼0.501, p¼ 0.041). CD9 expression levels
also correlated with the grade of the cancer samples with a stepwise decrease in expression
(r¼0.613, p¼ 0.007) from T1 (þ10 fold), T2 (þ2.14 fold), T3 (þ0.05 fold) to T4 (11.5 fold).
In addition, the T1 sample and the two T4 samples were removed from the dataset and T2 and T3
correlations were evaluated independently. When this was done, the correlation between ITGA2
and ITGB1 expression with the grade of the tumour remained statistically significant. However,
the correlation between CD9 expression and grade did not remain statistically significant.
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DISCUSSION
Identifying differentially expressed genes acts as an additional clinical tool that may be
used to diagnose patients and may influence the potential treatment decisions. The global dysre-
gulation observed in this gene expression study of the ECM indicates that substantial dysregula-
tion and remodelling of the ECM occur during colorectal pathogenesis and this can lead to
increased metastatic potential. The differential expression of fourteen genes which were statisti-
cally significant was identified. The largest dysregulation was observed in MMP7. MMP7
cleaves cell surface proteins, promotes adhesion of cancer cells, and increases the potential of
tumour metastasis37 and has been widely shown to be significantly higher than that of normal
cells in numerous studies both for colorectal carcinoma38–40 and other cancers.41–43 IL-8 was
also dysregulated and its overexpression has been detected in many carcinomas, including colo-
rectal cancer44 and is associated with poor prognosis.45 It has been suggested that tumour cells
produce IL-8 as an autocrine growth factor that promote tumour growth, tissue invasion, and
metastatic spread.46 ITGBL1 is a gene that is not frequently highlighted in the literature but has
been shown to have a role in breast cancer bone metastasis by activating TGFb signalling path-
way.47 MMP9 is a second protease from the initial panel that emerged as having differential
expression in malignant tissue in comparison to the matched normal tissue. Its overexpression
has been observed in colon cancer studies where it is largely associated with metastatic progres-
sion of colorectal cancer and overall poor prognosis.48,49 COL1A1 was observed to be increased
which may be contribute to abnormal tissue remodelling50 and increased tumour invasion
potential. ITGA2 has been linked to having a role in cell migration and metastasis by increasing
cofilin phosphorylation51,52 and was observed to be upregulated in the cohort, while CXCR2,
which is the receptor for LAMA1 and also a critical mediator of cellular senescence, was
observed to be overexpressed. Upregulated expression of SPARC was shown which conforms
with literature.53 RACK1 overexpression was also evident between samples and our research
group has shown it interacts with PTK2 and IGF1R to promote cellular migration.54 IGF1 gene
expression has been reported to be higher in colorectal cancer that that of normal mucosa.55,56
However, decreased levels were observed in this study in the malignant tissue. CEACAM1, a
gene shown to be upregulated in gastric cancer and has been shown to promote angiogenesis,57
was also observed to be overall decreased between normal and cancerous tissue. Restoration of
CEACAM1 expression in tumour cell lines often abolishes their oncogenicity in vivo, and there-
fore, this adhesion molecule has been regarded as a tumour suppressor.58 Decreased levels of
ITGA8 levels were observed in the cohort. ITGA8 has been shown to be one of a panel of genes
on an enriched molecular pathway in colorectal cancer.59 EGF and its receptor EGFR were both
downregulated in the study and both have been shown to be implicated in the growth and inva-
sion of colon cancer.60,61 The overexpression of EGFR in colon cancers without a KRAS muta-
tion has led to targeted therapies by blocking EGFR which has led to increased patient benefits.62
When analysed with regard to UICC classification of the disease, the pattern of dysregulation
became more pronounced and allowed for potential molecular markers to be identified. By show-
ing the differential expression with regard to UICC staging (Figure 3), a number of genes emerge
as being potential biomarkers for Stage I, Stage II, and Stage III/IV colorectal cancer. These
genes could become targets for specific treatment in patients presenting with these stages of colo-
rectal cancer or become an influencing factor in determining a patients’ diagnosis. The stages at
which genes become more influential in disease development and progression is shown (Figure 4).
Once expression levels were determined by experimental means, the panel of fourteen genes was
assessed for co-expressed genes (genes with similar expression patterns) using Pearson’s
Correlation test. Strength of relationship is determined by closeness to 1 (direct correlation) or 1
(inverse correlation). COL1A1 was identified to be co-expressed with both SPARC and RACK1.
COL1A1 and SPARC genes participate in ECM and cytoskeletal control and are also involved in
the carcinogenesis of many malignancies and both have been shown to be relevant for tumour
prognosis.63 Co-expression was also significant between MMP7 and ITGA2, ITGBL1 and SPARC,
ITGBL1 and EGF, and EGF and EGFR (Table III). A similar pattern of expression can be used to
identify co-expression networks which are of biological interest as co-expressed genes can be (a)
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controlled by the same transcriptional regulatory program (b) functionally related or (c) members
of the same pathway or protein complex.64 Furthermore, expression coordination between genes
involved in different functional categories suggests that the functional pathways can modulate each
other. Associations between the gene expression patterns of all genes and histopathological param-
eters recorded was also assessed. Strong associations between these parameters were observed
highlighting ECM genes which potentially could be used in aiding tumour phenotype predictions.
Graphical representation of the association of expression analysis with histopathological parameters
can be seen in Figure 5 where the genes identified could be used alone or as complement to exist-
ing CRC diagnostic tools for cancer development and/or progression.
CONCLUSION
This study highlights fourteen ECM genes, which show differential expression between
tumour tissue and matched normal colon mucosa. The genes which emerged as being different
have been previously shown in the literature to play key roles in the carcinoma process for a
range of individual cancers and in particular, colorectal carcinoma. A pairwise correlation
FIG. 4. Potential genetic biomarkers for CRC diagnosis based on UICC staging. Patients were grouped into categories
depending on the staging of the carcinoma.
FIG. 5. Association between gene expression and histopathological parameters. Pathological parameters can be found in
Table IV.
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pattern emerged also which showed that certain genes were co-expressed. Further to this, corre-
lations emerged between the gene expression pattern and clinic-pathological parameters which
were obtainable from pathology reports such as patient gender, tumour diameter, lymphovascu-
lar invasion, and nodal status. The genes highlighted in this study may represent important tar-
gets in colorectal carcinogenesis and could provide useful clinicopathological tools in the man-
agement and treatment of colorectal cancer. Expanding the patient cohort and genetic panel
could yield further potential biomarkers for metastasis and other treatment targets in colorectal
cancer. The successful utilisation of novel technologies such as microfluidics to solve biological
questions potentially allows us to maximise biomarker discovery rates and improve cancer
patient prognosis. qPCR integrated microfluidics provides numerous advantages for gene
expression: economies of scale, parallelisation and automation, and increased sensitivity and
precision that comes from small volume reactions. The microfluidic droplet technology used in
this study has the ability to analyse the expression levels of hundreds of genes across hundreds
of samples in a continuous flow regime while using reduced volumes of both sample and
reagents. The instrumentation will assist in the development of further microliter and nanoliter
microfluidic platforms which will progress molecular diagnostic advances in the biological
research field. Using this technology, we have shown that differential gene expression levels
greatly influence many biological conditions in both normal and abnormal circumstances and
can provide valuable information into the tissue and cell developmental behaviour in response
to environmental stimuli. The three-dimensional matrix, which supports, protects, and stabilises
all structures and cells, has diverse functions in the body. Accumulating evidence supports the
theory that the ECM is mechanically, biochemically, and functionally influential in the meta-
static behaviour of cancer cells. All structures within the matrix environment are inherently
linked. By identifying ECM related genes that influence the metastatic potential of cells, we
could potentially use these genes to predict prognosis. Comparing these findings with current
array-based studies supports the emerging panel of ECM genes as being dysregulated in colo-
rectal cancer. This highlights the potential of using microfluidic-based approaches for candidate
biomarker studies and is an example of one of the first applications of microfluidic technology
to colorectal cancer studies. The results of this gene expression profiling could stimulate an
interest in the direct use of expression profiles in the routine clinical setting. However, the data
outlined is preliminary. Further studies involving larger patient populations (including different
TABLE V. The dysregulated gene panel (Figure 2) was analysed as a combined cohort. Values shown in the table show
expression fold change between normal and cancerous samples and associated p-values (statistical significance).
Gene name
Patient cohort (n¼ 24)
Fold change Stat sig.
CEACAM1 4.1 0.048a
COL1A1 þ6.2 0.039a
CXCR2 þ4.0 0.02a
EGF 5.0 0.014a
EGFR 3.0 0.05a
ITGA2 þ4.0 0.007a
ITGA8 3.6 0.003a
ITGBL1 þ11.8 0.003a
IGF1 7.7 0.007a
IL-8 þ18.45 <0.001a
MMP7 þ31.1 <0.001a
MMP9 þ7.4 0.02a
RACK1 þ2.4 0.019a
SPARC þ3.8 0.033a
aStatistically significant (p< 0.05).
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tissue types) and confirmed biomolecular networks are merited giving the potential for more
informed diagnosis and early identification of metastasis in malignancies.
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